These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 33435905)

  • 1. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
    Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
    BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
    Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    Wagener-Ryczek S; Heydt C; Süptitz J; Michels S; Falk M; Alidousty C; Fassunke J; Ihle MA; Tiemann M; Heukamp L; Wolf J; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2020 May; 20(1):408. PubMed ID: 32397977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
    Dal Maso A; Lorenzi M; Roca E; Pilotto S; Macerelli M; Polo V; Cecere FL; Del Conte A; Nardo G; Buoro V; Scattolin D; Monteverdi S; Urso L; Zulato E; Frega S; Bonanno L; Indraccolo S; Calabrese F; Conte P; Pasello G
    Clin Lung Cancer; 2020 Jan; 21(1):1-14.e3. PubMed ID: 31601525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
    Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R
    Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
    Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
    Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy.
    Nakamura T; Nakashima C; Komiya K; Kitera K; Hirai M; Kimura S; Aragane N
    PLoS One; 2018; 13(12):e0209384. PubMed ID: 30550608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
    Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Yoshimoto N; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Hirata K; Koh Y; Kawaguchi T
    Lung Cancer; 2020 Jan; 139():80-88. PubMed ID: 31751804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer.
    Lin YT; Ho CC; Hsu WH; Liao WY; Yang CY; Yu CJ; Tsai TH; Yang JC; Wu SG; Hsu CL; Hsieh MS; Huang YL; Wu CL; Shih JY
    Cancer Med; 2024 Jan; 13(1):e6870. PubMed ID: 38140788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
    Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
    Huang CT; Lin CA; Su TJ; Yang CY; Tsai TH; Hsu CL; Liao WY; Chen KY; Ho CC; Yu CJ
    BMC Cancer; 2023 Mar; 23(1):234. PubMed ID: 36915101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors.
    Li C; Jia R; Liu H; Zhang B; Wang C
    Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
    Iwama E; Sakai K; Azuma K; Harada D; Nosaki K; Hotta K; Nishio M; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
    Cancer Sci; 2018 Dec; 109(12):3921-3933. PubMed ID: 30289575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
    Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
    Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
    Wang Z; Chen R; Wang S; Zhong J; Wu M; Zhao J; Duan J; Zhuo M; An T; Wang Y; Bai H; Wang J
    PLoS One; 2014; 9(11):e110780. PubMed ID: 25405807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.